MKGAF - MERCK Kommanditgesellschaft auf Aktien

Other OTC - Other OTC Delayed Price. Currency in USD
0.00 (0.00%)
At close: 9:55AM EST
Stock chart is not supported by your current browser
Previous Close120.63
Bid0.00 x 0
Ask0.00 x 0
Day's Range120.63 - 120.63
52 Week Range96.00 - 120.90
Avg. Volume323
Market Cap52.534B
Beta (3Y Monthly)0.55
PE Ratio (TTM)23.28
EPS (TTM)5.18
Earnings DateN/A
Forward Dividend & Yield1.40 (1.16%)
Ex-Dividend Date2019-04-29
1y Target EstN/A
  • Reuters

    UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover

    German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October. Merck said 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would come in between 4.23 billion euros and 4.43 billion euros ($4.7-$4.9 billion), up from a previous prediction of between 4.15 billion euros and 4.35 billion euros. Shares in Merck were down 1.55% at 0828 GMT.

  • If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today
    Simply Wall St.

    If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today

    Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

  • MarketWatch

    Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial

    Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival. The current standard of care is chemotherapy. The German drugmaker and Pfizer formed an alliance in 2014 to develop and commercialize Bavencio, which was first approved by the U.S. Food and Drug Administration in 2017 as a treatment for metastatic Merkel cell carcinoma. Shares of Pfizer have fallen 15.44% year-to-date, while the S&P 500 is up about 23% for the year.

  • Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
    Simply Wall St.

    Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MERCK...

  • Reuters

    Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

    Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation last year.

  • Moody's

    Merck KGaA -- Moody's: Versum shareholders approve acquisition by Merck KGaA

    Merck KGaA ("Merck") announced that its transaction with Versum Materials, Inc ("Versum") had been approved at a special meeting among Versum's shareholders. Merck had signed a definitive agreement to acquire Versum for a consideration of $53 in cash in April this year, notes Moody's.

  • Reuters

    Merck KGaA sees currencies supporting 2019 outlook

    FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth ...


    Keeley Funds Comments on Versum Materials

    Guru stock highlight

  • Reuters

    UPDATE 2-European shares hit by U.S. tariff threat, growth jitters (April 9)

    European shares slid on Tuesday, with most sectors falling after the United States threatened to slap tariffs on goods from the European Union, with worries compounded by the IMF cutting its global growth forecast. The U.S. Trade Representative proposed a list of European Union products late on Monday on which to slap tariffs in retaliation to more than $11 billion of EU subsidies to Airbus the World Trade Organization has found cause "adverse effects" to the United States.

  • Benzinga

    Merck KGaA Signs Versum Buyout Deal; Entegris Receives Termination Payment

    The business combination received unanimous approval from the boards of the German pharmaceutical company and Versum, Merck said in a Friday press release. Versum is a supplier of process chemicals, gases and semiconductor manufacturing equipment.

  • Reuters

    Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals

    Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.

  • Benzinga

    Versum Materials Says Revised Merck KGaA Buyout Proposal 'Superior' To Entegris Offer

    Versum Materials, Inc . (NYSE: VSM ) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  ...

  • Merck KGaA wins Versum's support for sweetened $6.5 billion offer

    Merck KGaA wins Versum's support for sweetened $6.5 billion offer

    Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets. "This proposal constitutes a 'Superior Proposal' as defined in Versum's previously announced merger agreement with Entegris, Inc.," Versum said in a statement on Monday. On a per share basis, Germany's Merck offered $53, up from $48 previously, after reviewing business data and following meetings between Merck Chief Executive Stefan Oschmann and Versum Chairman Seifi Ghasemi, filings showed.

  • Reuters

    Merck KGaA raises offer for Versum Materials to $53 per share

    Versum Materials Inc said on Monday that Merck KGaA had raised its offer for the company to $53 per share from $48. Merck had launched a hostile $5.9 billion all-cash takeover offer for Versum last month ...

  • Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

    Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

    Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.

  • Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

    Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

    Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

  • Reuters

    Versum opens books, begins to warm to rival suitor Merck KGaA

    "Merck’s proposal could reasonably be expected to result in a superior proposal," Versum, a maker of chemicals for the semiconductor industry, cited its board as saying in a statement on Friday. The board "has authorized Versum's management and its advisers to engage in further discussions with, and provide non-public information to, Merck," the statement added.